To order this detailed 300+ page report, please visit this
- https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html
Key Inclusions
§
An assessment of
microbiome contract manufacturing capability in different regions, based on a
number of relevant parameters, such as number of CMOs, number of completed /
active / planned clinical trials, number of patients enrolled, number of
manufacturing facilities, number of companies offering API / FDF manufacturing,
number of companies having capabilities for preclinical / clinical / commercial
manufacturing, number of companies dedicated to aerobic / anaerobic fermentation,
installed manufacturing capacity, and number of in-house players.
§
A list of nearly 50
microbiome-focused drug developers that are anticipated to partner with
contract manufacturers and have been shortlisted on the basis of parameters,
such as developer strength (which takes into account the company's size and its
experience in this field), company's pipeline strength and maturity (based on
the number of pipeline drugs and affiliated stage of development) and the
availability of in-house manufacturing capabilities.
§
A detailed clinical
trial analysis of more than 150 completed, ongoing and planned studies of
various microbiome therapeutics sponsored by both industry and non-industry
players; it highlights prevalent trends across various relevant parameters,
such as trial registration year, trial phase, number of patients enrolled,
trial recruitment status, study design and trial focus, highlighting leading
sponsors (in terms of number of trials conducted), type of organization, popular
therapeutic areas, and regional distribution of trials.
§
An estimate of the
overall, installed capacity for manufacturing of microbiome therapeutics,
taking into consideration the capabilities of various stakeholders, based on
data gathered via secondary and primary research; it presents the distribution
of available capacity in terms of quantity of microbiome therapeutics produced
(in liters, per year), across important market segments, such as company size
(small-sized, mid-sized and large companies), scale of operation (clinical and
commercial), and key geographical regions (North America, Europe and
Asia-Pacific and rest of the world).
§
An informed estimate
of the annual clinical demand for microbiome therapeutics, taking into account
the target patient population in ongoing and planned clinical trials of
microbiome therapeutics, sponsored by both industry and non-industry players.
§
A qualitative
analysis, highlighting the various factors that need to be taken into
consideration by microbiome therapeutics developers while deciding whether to
manufacture their respective products in-house or engage the services of a CMO.
§
A review of the
varied microbiome-focused initiatives of big pharma players (shortlisted from
the top 20 pharmaceutical companies as of 2019), featuring a [A] heat map
representation that highlights microbiome therapeutics under development (in
partnership with core microbiome-focused entities), along with information on
funding, partnership activity, and
diversity of product portfolio (in terms of disease indication(s) being treated
and focus therapeutic area(s)), and [B] a spider web representation, comparing
the initiatives of big pharma players on the basis of multiple relevant
parameters.
The report also features the likely distribution
of the current and forecasted opportunity across important market segments,
mentioned below:
§ Type
of Product Manufactured
§ Active
Pharmaceutical Ingredients (APIs)
§ Finish
Drug Formulations (FDFs)
§ Type
of Type of Formulation
§ Solid
Formulations
§ Oral
Liquids
§ Injectables
§ Others
§ Scale
of Operation
§ Clinical
§ Commercial
§ Company
Size
§ Small-sized
§ Mid-sized
§ Large
§ Key
Geographical Regions
§ North
America
§ Europe
§ Asia-Pacific
and Rest of the World
To request sample pages, please visit this -
https://www.rootsanalysis.com/reports/306/request-sample.html
Key
Questions Answered
§ Who
are the leading CMOs offering microbiome contract manufacturing services,
across the world?
§ What
are the key challenges faced by microbiome contract manufacturers?
§ Who
are the most likely partners (microbiome-based live biotherapeutic drug
developers) for microbiome contract manufacturers?
§ What
is the annual clinical demand for microbiome-based live biotherapeutic products?
§ What is the current, installed contract
manufacturing capacity for live biotherapeutics?
§ What
are the key factors influencing the make (manufacture in-house) versus
buy (outsource) decision in this field?
§ What
are the various initiatives undertaken by big pharma players in this domain?
§ What
percentage of live biotherapeutics manufacturing
operations are outsourced to service providers?
§ How
is the current and future market opportunity likely to be distributed across
key market segments?
§
What are the anticipated future trends related to live biotherapeutics manufacturing?
You
may also be interested in the following titles:
1.
HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030
2.
Antibody Contract Manufacturing Market, 2020 – 2030
3.
The Human Microbiome
Market: Focus on Therapeutics (including gut-brain axis targeting drugs),
Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030
Contact
Us
Gaurav
Chaudhary
+1
(415) 800 3415
gaurav.chaudhary@rootsanalysis.com
